Michael Keller received his training in Chemistry/Biochemistry from the ETH Zürich (Diploma in Natural Sciences) and Imperial College London (MSc in Chemical Research). He carried out a PhD with Prof. M. Mutter at the University of Lausanne in Bioorganic Chemistry before taking up a Lectureship in Biological Chemistry at the University of Lausanne. He then moved on to Imperial College London as Academic Visitor where he co-founded the Anglo-Japanese Biotech company IC-Vec Ltd. which specialized in novel liposome based siRNA delivery approaches. In 2007 he joined Novartis Pharma AG in Basel where he built up the siRNA delivery unit. In 2017 he moved to F. Hoffmann La Roche Ltd. in Basel to work on disruptive delivery approaches for locked nucleic acid antisense oligonucleotides (LNA-ASO). His main interest are Nanopharmaceuticals, biomolecular interactions, supramolecular chemistry and multidisciplinary approaches to advance disruptive scientific approaches for nucleic acid based APIs into the clinics.